Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ZYME Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 02, 2026
Report Source: 2026 1st Quarter Report
Zymeworks Inc. Stock Analysis ZYME
United States Health Care Small Cap Report: Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Read More Zymeworks Inc (ZYME) Chart
Key Statistics of Zymeworks Inc (ZYME)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$22.90Volume
623.54KP/E Ratio (TTM)
-52 Week Range
Market Cap
1.78BAvg. Volume
706.26KDividend Yield
-Financial Metrics & Statements of Zymeworks Inc (ZYME)
FAQ's for Zymeworks Inc (ZYME)
- According to Musaffa’s Shariah screening methodology, Zymeworks Inc (ZYME) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Zymeworks Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Zymeworks Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Zymeworks Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Zymeworks Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Zymeworks Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.